Vor Biopharma, Inc. (VOR)

Vor Biopharma's stock experienced several notable events in the past six months. The company reported inducement grants under Nasdaq Listing Rule 5635(c)(4) on multiple occasions. On March 30, 2026, Vor Biopharma reported its Fourth Quarter and Full Year 2025 Financial Results and provided a corporate update, including dosing the first patient in the global Phase 3 UPSTREAM SjD trial and a $75.0 million private placement with TCGX. Director RA Capital Management, LLC executed significant sales of Vor Biopharma stock in April 2026. Multiple analysts updated their views on VOR following clinical and financing developments, with some reducing price targets. As of May 7, 2026, the stock had decreased by 4.57% in the past month, but since the beginning of 2026, the stock had increased by 22.94%, and over the past 12 months, the stock gained 50.1%.

Vor Biopharma's products and services do not exhibit traditional demand seasonality. The demand for its product is driven by clinical trial progress, regulatory approvals, and the medical need for treating specific autoimmune conditions. Historically, December has shown the highest probability of positive returns for VOR stock, while April has the lowest probability of positive returns.

Vor Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on transforming the treatment of autoimmune diseases by advancing telitacicept through Phase 3 clinical development and commercialization. Telitacicept inhibits BLyS (BAFF) and APRIL to reduce autoreactive B cells and autoantibody production. Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG), and Vor Biopharma has a license agreement with RemeGen Co., Ltd. for its exploitation. The company is also pursuing additional regulatory filings in China for primary Sjögren's disease (SjD) and IgA nephropathy (IgAN).

Vor Biopharma Inc. is headquartered in Boston, Massachusetts, United States. Telitacicept is approved and marketed in China through collaboration with RemeGen, and Vor Biopharma is engaged in global development programs, including a global Phase 3 clinical trial for generalized myasthenia gravis (gMG) across the United States, Europe, and South America. The company has also dosed the first patient in a global Phase 3 UPSTREAM SjD Registrational Trial of telitacicept in primary Sjögren's disease.

Vor Biopharma generally holds a positive reputation among analysts, with a consensus rating of "Moderate Buy". Analysts have expressed optimism about the company's earnings prospects and its strategic pivot into autoimmune diseases with telitacicept. However, some "bearish" sentiments highlight concerns about the market potential for telitacicept, a limited pipeline, and the company's financial strength. The significant selling of shares by Director RA Capital Management, LLC in April 2026, could impact reputation.

Vor Biopharma's ownership structure includes a mix of institutional, venture capital/private equity (VC/PE) firms, individual insiders, and the general public. Institutions hold approximately 39.3% of the shares, while VC/PE firms own about 17.1%. Individual insiders hold around 2.19%, and the general public accounts for approximately 41.3% of the shares. Major institutional shareholders include RA Capital Management, L.P., Forbion Capital Partners B.V., The Vanguard Group, Inc., and BlackRock, Inc. Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 768%.